vs
Side-by-side financial comparison of PROTHENA CORP PUBLIC LTD CO (PRTA) and Silo Pharma, Inc. (SILO). Click either name above to swap in a different company.
PROTHENA CORP PUBLIC LTD CO is the larger business by last-quarter revenue ($21.0K vs $18.0K, roughly 1.2× Silo Pharma, Inc.). On growth, Silo Pharma, Inc. posted the faster year-over-year revenue change (0.0% vs -99.0%). Over the past eight quarters, Silo Pharma, Inc.'s revenue compounded faster (0.0% CAGR vs -35.2%).
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
The Pharma Documentation Ring (P-D-R), founded in 1958, is a think tank of information and knowledge-management professionals representing major research-based pharmaceutical companies. The association has four aims:Promote exchange of knowledge among members Encourage commercial development of new information services and systems Jointly assess new and existing products and services Provide a forum for the information industry
PRTA vs SILO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $18.0K |
| Net Profit | — | $-1.1M |
| Gross Margin | — | -14.8% |
| Operating Margin | — | -6388.2% |
| Net Margin | — | -6160.5% |
| Revenue YoY | -99.0% | 0.0% |
| Net Profit YoY | 62.7% | -19.6% |
| EPS (diluted) | — | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | — | ||
| Q3 25 | $2.4M | $18.0K | ||
| Q2 25 | $4.4M | $18.0K | ||
| Q1 25 | $2.8M | $18.0K | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $970.0K | $18.0K | ||
| Q2 24 | $132.0M | $18.0K | ||
| Q1 24 | $50.0K | $18.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-36.5M | $-1.1M | ||
| Q2 25 | $-125.8M | $-1.2M | ||
| Q1 25 | $-60.2M | $-1.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-59.0M | $-928.8K | ||
| Q2 24 | $66.9M | $-931.8K | ||
| Q1 24 | $-72.2M | $-801.7K |
| Q4 25 | — | — | ||
| Q3 25 | — | -14.8% | ||
| Q2 25 | — | 91.9% | ||
| Q1 25 | — | 91.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 91.9% | ||
| Q2 24 | — | 91.9% | ||
| Q1 24 | — | 91.9% |
| Q4 25 | — | — | ||
| Q3 25 | -1666.3% | -6388.2% | ||
| Q2 25 | -1914.4% | -6926.8% | ||
| Q1 25 | -2319.0% | -6069.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6857.0% | -5603.6% | ||
| Q2 24 | 44.2% | -5563.2% | ||
| Q1 24 | -163056.0% | -4879.1% |
| Q4 25 | — | — | ||
| Q3 25 | -1513.1% | -6160.5% | ||
| Q2 25 | -2845.4% | -6681.2% | ||
| Q1 25 | -2128.5% | -5721.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6082.6% | -5152.9% | ||
| Q2 24 | 50.7% | -5169.4% | ||
| Q1 24 | -144478.0% | -4447.3% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.68 | $-0.12 | ||
| Q2 25 | $-2.34 | $-0.19 | ||
| Q1 25 | $-1.12 | $-0.23 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.10 | $-0.22 | ||
| Q2 24 | $1.22 | $-0.31 | ||
| Q1 24 | $-1.34 | $-0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.5M | $5.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $280.5M | $5.0M |
| Total Assets | $326.8M | $6.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $307.5M | — | ||
| Q3 25 | $330.8M | $5.9M | ||
| Q2 25 | $371.4M | $6.3M | ||
| Q1 25 | $417.9M | $5.5M | ||
| Q4 24 | $471.4M | — | ||
| Q3 24 | $519.3M | $8.0M | ||
| Q2 24 | $564.1M | $7.6M | ||
| Q1 24 | $546.5M | $6.7M |
| Q4 25 | $280.5M | — | ||
| Q3 25 | $295.0M | $5.0M | ||
| Q2 25 | $324.3M | $4.9M | ||
| Q1 25 | $437.7M | $4.0M | ||
| Q4 24 | $486.9M | — | ||
| Q3 24 | $534.4M | $6.8M | ||
| Q2 24 | $581.9M | $6.0M | ||
| Q1 24 | $502.4M | $5.3M |
| Q4 25 | $326.8M | — | ||
| Q3 25 | $352.6M | $6.4M | ||
| Q2 25 | $399.1M | $6.7M | ||
| Q1 25 | $495.3M | $5.9M | ||
| Q4 24 | $547.1M | — | ||
| Q3 24 | $595.3M | $8.6M | ||
| Q2 24 | $645.6M | $8.0M | ||
| Q1 24 | $623.2M | $6.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-163.6M | $-955.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-163.6M | — | ||
| Q3 25 | $-40.6M | $-955.5K | ||
| Q2 25 | $-46.3M | $-1.3M | ||
| Q1 25 | $-53.4M | $-1.6M | ||
| Q4 24 | $-150.1M | — | ||
| Q3 24 | $-45.2M | $-1.3M | ||
| Q2 24 | $16.0M | $-731.8K | ||
| Q1 24 | $-73.1M | $-838.2K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
